MK-677 research: what the published trials report
The short version: MK-677 reliably raises IGF-1 in trials. Lean mass gains are real but modest. Side effects are not subtle. It is not approved for any indication.
TL;DR
- MK-677 is an oral growth hormone secretagogue developed by Merck and never approved.
- Trials show consistent IGF-1 elevation and small lean-mass gains in older adults.
- Common trial side effects include water retention, mild blood-sugar elevation, and increased appetite.
What it is
MK-677, also called ibutamoren, is a small molecule taken by mouth (in plain English: most peptides have to be injected, but this one survives the stomach because it is not a peptide). It mimics ghrelin (in plain English: the body's "hunger and growth-hormone-release" hormone). It binds the same receptor as ghrelin and triggers the pituitary to release growth hormone.
How it works
Picture the pituitary gland as a vending machine for growth hormone. Ghrelin is one of the buttons. MK-677 is a finger that presses that button on a steady, daily schedule. The pituitary releases growth hormone, which raises IGF-1 in the liver. Because the molecule survives oral dosing, it produces a more sustained signal than injected peptides. That sustained signal is also why the side effect profile differs (Murphy et al., J Endocrinol, 1997).
Who asks about it
People come to MK-677 because it is the only oral compound in the growth-hormone-peptide conversation. The question they bring is usually whether oral convenience is worth the trade-off in side effects.
What the research says
A two-month trial in healthy older adults showed daily oral MK-677 raised IGF-1 by roughly 40 to 90 percent and increased lean mass by about 1 to 1.5 kg. Fat mass did not change meaningfully, and fasting blood sugar rose modestly (Nass et al., Ann Intern Med, 2008). Earlier dose-response work confirmed the pituitary signal in healthy young adults (Murphy, J Endocrinol, 1997). Sleep architecture data is mixed; some trials show small increases in deep sleep, others none.
What to know before considering it
Side effects in published trials are not subtle. About 4 in 10 participants reported water retention, increased appetite, or muscle aches. Fasting blood sugar can rise. People with insulin resistance, active malignancy, or fluid-overload conditions should not use it. Any peptide or secretagogue access requires a licensed clinician and baseline labs.
The Halftime POV
MK-677 has more trial data than most growth hormone peptides because Merck advanced it through phase II development. The trade-off is honest: the IGF-1 signal is reliable, and so are the side effects. It is not a casual choice.
Related reading:
- How MK-677 stimulates growth hormone: the ghrelin pathway
- MK-677 side effects: water retention, insulin, appetite, and more
- MK-677 (Ibutamoren): an oral growth-hormone secretagogue
FAQ
Q: What does MK-677 research show? A: Published trials show MK-677 raises IGF-1 by about 40 to 90 percent for as long as it is taken. Older adults gained roughly 1 to 1.5 kg of lean mass over two months in one trial. Sleep architecture data is mixed.
Q: Are there MK-677 human trials? A: Yes. Merck developed MK-677 (ibutamoren) and ran several trials in healthy older adults and in pediatric growth hormone deficiency. The compound was never approved for any indication.
Q: Is MK-677 FDA-approved? A: No. MK-677 is investigational and was never granted FDA approval. The compounded oral form is not FDA-approved either and is accessed only through state-licensed 503A compounding pharmacies under physician prescription.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. We'll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we'll email you when we're live.
Sources
Frequently asked questions
What does MK-677 research show?
Published trials show MK-677 raises IGF-1 by about 40 to 90 percent for as long as it is taken. Older adults gained roughly 1 to 1.5 kg of lean mass over two months in one trial. Sleep architecture data is mixed.
Are there MK-677 human trials?
Yes. Merck developed MK-677 (ibutamoren) and ran several trials in healthy older adults and in pediatric growth hormone deficiency. The compound was never approved for any indication.
Is MK-677 FDA-approved?
No. MK-677 is investigational and was never granted FDA approval. The compounded oral form is not FDA-approved either and is accessed only through state-licensed 503A compounding pharmacies under physician prescription.
Keep reading
A licensed physician can build a protocol from your own labs.
Membership from $69/mo, including your onboarding panel. Each protocol is its own monthly subscription.